Effects of Levodopa on Speech Intensity and Rate in Parkinson’s Disease
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Background

Results

• Levodopa is the primary medication for the treatment of general
limb motor symptoms in Parkinson’s disease (PD), however its
effects on speech intensity and rate have been inconsistent 1,2,3.
• Two recent studies of the effects of levodopa on dysphonia and
speech disfluency found that responsiveness was significantly
associated with the severity of these speech symptoms 4,5.
• Duration of PD diagnosis and duration of levodopa use may affect
the response to levodopa and its effects on speech. It has been
suggested that speech becomes levodopa resistant, particularly
after 10 years of use6,7.

Objectives
To examine the effects of levodopa on speech intensity and speech
rate and to explore the potential association between levodopa
responsiveness and the severity of these speech symptoms in PD.

Methods
• 54 individuals with PD (IWDPs) and 11 age-matched healthy
controls (HC) participated in this study.
• IWPDs were evaluated OFF-medication, at least 12 hours after
their last dose of levodopa. After testing, IWPDs took a controlled
dose of 300 mg of levodopa. ON-medication condition testing
began 1 hour after this dose.
• IWPDs had a mean age of 65.94 years (SD =7.38, range 47-82
years). Demographic information is presented in Table 1. Controls
have a mean age of 62.09 years (SD = 6.55, range 52-72).
• Speech tasks were categorized as: 1) syllable repetition (10x of
puh, tuh, kuh, 5x ai slow and fast), 2) reading sentences (the
Rainbow passage and the Patty sentence.
• Praat was used to obtain average speech intensity (dB SPL) and
duration (ms) of each speech task (the first 5 or 10 syllables of
each syllable repetition task and each of the 4 selected sentences).
• T-tests and correlations were used to evaluate differences between
groups/medication conditions and associations between selected
variables.

Levodopa and Speech Intensity
• Administration of levodopa medication produced a significant increase in speech intensity in the IWPD group, illustrated in Table 2.
• Negative correlations suggest that IWPDs with more severe (lower) speech intensity may experience a larger medication-related increase than those with less
severe (higher) speech intensity (Figure 1).
• IWPDs were split into Severe “Low Intensity” and Mild “High Intensity” groups based on their OFF-medication speech intensity relative to the HC intensity average.
• Individuals were divided based on a cut-off score 2SD below the average HC speech intensity.
• The Severe group had significantly larger medication-related (improvement) in speech intensity (Figure 2).
Table 2. Means and standard deviations of speech intensity
Task

IWPD OFF
Mean (SD)

IWPD ON
Mean (SD)

Off-On

Off-Control

p-value

HCs
Mean (SD)

ppp10

66.97 (3.72)

68.37 (4.44)

.005*

69.45 (4.31)

.028*

kkk10

66.24 (4.17)

67.53 (4.09)

.002*

68.97 (3.95)

.025*

aiFast

71.25 (4.19)

72.92 (4.36)

.000*

72.49 (3.88)

.183

Rain1

66.12 (4.12)

67.03 (4.61)

.052

68.99 (3.31)

.017*

Rain3

64.57 (3.86)

65.70 (4.45)

.006*

67.44 (2.85)

.012*

P-value

Figure 2. Average levodopa medication-related change in
speech intensity for Mild and Severe subgroups

Figure 1. Scatterplot of medication-related change in
intensity vs. the OFF-medication speech intensity

Levodopa and Speech Time/Rate
• Levodopa was not found to significantly affect speech time/rate in the PD group. IWPDs were not found to be significantly different from controls (Table 3).
• The significant negative correlations suggest that IWPDs with slower rate of speech experience a larger medication-related change in speech time than those who
speak faster (Figure 3).
• IWPDs were split into ”Fast” and “Slow” subgroups based on their OFF-medication speech time relative to the HC average speech time (-1SD).
• The Slow group had significantly larger medication-related (improvement), relative to the Fast group, for several of the speech tasks (Figure 4 and 5).

Conclusions

Table 3. Means and standard deviations of speech time/rate
Task
ttt10
aiSlow
Patty
Rain2

OffControl

IWPD OFF
Mean (SD)

IWPD ON
Mean (SD)

Off-On
p-value

HCs
Mean (SD)

1.90 (.43)

1.83 (0.32)

.182

1.71 (.28)

.147

0.91 (.22)

0.86 (0.20)

.058

0.99 (.23)

.274

2.03 (0.28)

2.02 (0.31)

.548

2.04 (0.29)

.983

3.83 (1.13)

3.91 (1.18)

.404

3.66 (0.54)

.614

P-value

Figure 3. Scatterplot of medication-related change vs.
the OFF-medication speech time/rate

• In this group of IWPDs, levodopa had a significant effect
on speech intensity but not speech time/rate. However,
variation in severity appeared to influence the results.
• An important relationship was observed between the
medication-related changes in speech intensity/rate and
the OFF-medication severity of these symptoms.
• This study provides additional support for the “Speech
Severity Responsiveness Hypothesis” which proposed that
individuals with more severe speech symptoms show a
greater degree of response to levodopa medication.

Table 1. Demographic information for IWPDs
Mean (SD)

Acknowledgements

Range

Age

65.94 (7.38)

47-82

Duration of diagnosis

9.15 (4.18)

2-16

Duration of levodopa use

7.45 (3.86)

2-16
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UPDRS OFF-medication
UPDRS ON-medication

29.94(8.39)
16.25 (7.12)

14-51

3.
4.

3-32

5.

Levodopa equivalent dose

1027.2 (449.2)

300-2200

6.

Figure 4. Average levodopa medication-related change in
speech rate for Fast and Slow subgroups

Figure 5. Average levodopa medication-related change in
speech rate for Fast and Slow subgroups
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